SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as investors weigh recent acquisition activity against broader macroeconomic headwinds, including geopolitical tensions and fluctuating construction market sentiment. Despite the bearish pressure, the community remains actively divided, with many long-term shareholders continuing to express confidence in CEO Brad Jacobs' consolidation strategy while others closely monitor for the next M&A catalyst or integration updates.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and price appreciation following its recent NYSE listing, with investors actively debating whether the high premium over its reported net asset value is justified by its exclusive exposure to high-profile private AI companies like Anthropic and OpenAI. Community discussion is dominated by the impact of a mandatory six-month lockup period on the majority of shares, which has created a tight float and sparked intense speculation about potential for further momentum or a sharp correction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is under significant downward pressure as investors rotate out of growth stocks amid geopolitical instability and skepticism regarding the execution of its latest AI and infrastructure initiatives. The community remains deeply divided, with some buyers viewing the current price action as a long-term accumulation opportunity, while others express frustration over the stock's recent technical breakdown and the company's dependency on speculative future projects.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is capturing significant market attention as users actively engage with its updated lending protocol, allowing them to borrow against staked SOL while simultaneously participating in its broader ecosystem of meme tokens and community-verified projects. Discussions are currently dominated by high APY lending opportunities and the ongoing expansion of its verified token list, fueling diverse sentiment ranging from strong platform loyalty to speculative debates over its long-term tokenomics.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant insider buy by Kevin Tang, which has ignited renewed speculation about a potential buyout and strategic pipeline development. The community is actively debating the company's long-term valuation, the mysterious status of the AUR200 program, and the leadership of CEO Peter Greenleaf ahead of the upcoming earnings report.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. is trending as shareholders recently approved its merger with Xanadu Quantum Technologies, a milestone expected to establish the first publicly traded photonic quantum computing company under the ticker XNDU. Community discussion is heavily focused on the deal's potential for a low-float short-term squeeze, strategic partnerships with major tech industry leaders, and potential government funding support.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

Investors are actively debating the merits of Harvest Diversified High Income Shares ETF, frequently highlighting it as a core component for income-focused portfolios and tax-efficient strategies within Canadian tax-advantaged accounts. While some community members view market dips as opportunities for accumulation, others are engaged in broader discussions regarding the performance of its underlying covered call strategy and its role in long-term wealth building.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a massive Q4 booking report that significantly exceeded expectations, signaling robust long-term demand for AI-driven lithography equipment. Community discussion remains heavily focused on the company's unassailable moat as a 'foundational' AI player, with many traders debating the sustainability of current valuation highs despite strong buyback announcements and increased backlog visibility.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

The community is actively trading the high volatility of $MSTZ, with many traders sharing their success in utilizing it as a tactical hedge or scalp against the price action of $MSTR and broader crypto market movements. Discussions highlight a split between those treating the asset as a quick day-trading instrument to capitalize on intraday pullbacks and those holding longer-term positions, while others debate the inherent risks of leveraged products in a volatile sector.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is attracting significant institutional interest and investor optimism following a series of new stake acquisitions by prominent investment firms and continued endorsements from analysts, even as the stock navigates a post-IPO period marked by lockup expiration concerns. Community sentiment is largely focused on the company's strong position in the AI security and SASE markets, with bulls viewing recent price volatility as a potential accumulation opportunity rather than a reflection of operational weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies

SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.

<ul class="summary-bullets"><li>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.&nbsp;</li><li>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year.</li><li>Earlier this week, Sarepta also said that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its DMD gene therapy Elevidys.</li></ul><p>Sarepta Therapeutics (SRPT) said on Thursday that it intends to make certain submissions to the U.S. Food and Drug Administration regarding two of its Duchenne muscular dystrophy therapies by the end of April, in a move applauded by Wall Street.</p><p>Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, with the help of data from a confirmatory late-stage study.</p><p>The company said that the FDA has confirmed that data from the trial can be submitted as part of the application. However, the adequacy of the data to support conversion to traditional approval will be a matter of review, the company said.</p><h2 class="st-heading-2">Analyst Takeaway</h2><p>Oppenheimer analyst Andreas Argyrides sees the sNDA filing as positive as it removes the risk of Amondys/Vyondys being pulled from the market for the next year. The analyst added that it also signals positive FDA feedback during a meeting, pointing to potential sNDA approval.</p><p>The firm reiterated an ‘Outperform’ rating on Sarepta with a price target of $37 on the shares.</p><h2 class="st-heading-2">About Vyondys And Amondys</h2><p>Vyondys 53 and Amondys 45 are both FDA-approved, weekly intravenous antisense oligonucleotide therapies from Sarepta for Duchenne muscular dystrophy (DMD), a severe, progressive genetic disorder primarily affecting young boys, characterized by muscle degeneration. Both therapies now have an accelerated approval.</p><p>While Accelerated Approval (AA) allows faster market access for drugs treating serious conditions, based on surrogate endpoints that likely predict clinical benefit, Traditional Approval requires direct evidence of clinical benefit. Accelerated approval requires post-marketing confirmatory trials to prove clinical efficacy to prevent the approval from being withdrawn.</p><p>With additional data from its confirmatory late-stage trial, Sarepta is now seeking to shift the approval type to traditional for the two DMD therapies.</p><h2 class="st-heading-2">Sarepta’s Update For Elevidys</h2><p>Earlier this week, Sarepta also <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-shares-rise-as-company-begins-enrollment-in-gene-therapy-safety-enhancement-study/cZ3PezERIQd">said</a> that screening and enrollment are underway in a cohort of its study aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>FDA-approved Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> is down 79% over the past 12 months.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 

Equity

Sarepta is now looking to submit supplemental new drug applications (sNDA) seeking conversion of the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals. 


Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer

Oppenheimer reiterated an "outperform" rating and set a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday...

Sarepta Provides Regulatory Update on AMONDYS 45 and VYONDYS 53

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug...

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.

KROS: Is the Discount Book Value a Value Trap?

Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.

KROS Stock: What to Know About Rinvatercept in DMD

Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.

SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study

Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.

<ul class="summary-bullets"><li>Sarepta is looking to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</li><li>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li><li>While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</li></ul><p>Shares of Sarepta Therapeutics, Inc. (SRPT) edged up nearly 1.5% on Monday after the company said that screening and enrollment are underway in a cohort of its study, aimed at developing an enhanced safety protocol for its gene therapy, Elevidys, in non-ambulant individuals with Duchenne muscular dystrophy.</p><p>Data from the cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks of acute liver injury and acute liver failure associated with Elevidys in DMD patients who cannot walk.</p><h2 class="st-heading-2">Gene Therapy Study Details</h2><p>Sarepta is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-screening-and-enrollment-are-underway-endeavor">looking</a> to enroll about 25 Duchenne muscular dystrophy patients who are non-ambulatory in the cohort.</p><p>Patients enrolled in the cohort will be administered peri-infusion sirolimus 14 days before Elevidys administration and will continue to receive it for 12 weeks after Elevidys, the company said.</p><p>Elevidys is the only approved gene therapy for Duchenne, a severe, progressive genetic muscle-wasting disease, primarily affecting young boys.</p><p>Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths. While the company resumed shipments to ambulatory patients after a temporary pause in July 2025, it is now working to address the safety concerns in patients who cannot walk.</p><h2 class="st-heading-2">Street Consensus</h2><p>Last week, Mizuho raised the firm's price target on Sarepta to $31 from $26 and kept an ‘Outperform’ rating on the shares, while Citi raised the its price target on Sarepta to $9 from $8 and kept a ‘Sell’ rating on the shares.</p><p>According to data from Koyfin, the average 12-month price target on the stock is $20.61, representing a potential upside of about 24% from current trading levels, as of the time of writing.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around SRPT stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.</p><p><a href="https://stocktwits.com/symbol/SRPT">SRPT stock</a> has fallen nearly 84% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-halts-v3-supercharger-production-in-new-york/cZ3PEpcRIQb">Tesla Halts V3 Supercharger Production In New York In Favor Of Faster, Rival EV-Compatible Variant</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study

Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Current Price	$16.69
Prev Close	$16.65
Open	$16.68
Dividend Yield	0.00%
50-Day Moving Average	$18.99
Beta	1.16
Avg. Volume	2.38M
PE Ratio	-1.98

52-Week High	$76.67
52-Week Low	$10.42
Market Capitalization	$1.75B
EPS (Annual)	-$7.13
Price to Book	1.54
Revenue Per Employee	$2.63M

SRPT
Sarepta Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News

SRPTSarepta Therapeutics Inc